slide 55 of 67
	Three randomized, parallel group, double-blind, placebo-controlled trials All trials positive on several domains Two studied memantine monotherapy Phase 3, multicenter, randomized, double-blind, placebo-controlled trial performed in the United States with 252 outpatients with moderate to severe AD (Reisberg, etal) Phase 3, double-blind, placebo-controlled trial of memantine 10 mg vs placebo in 166 moderately severe to severely demented, care-dependent nursing home patients (Winblad, etal) One studied patients receiving a stable dose of donepezil (Tariot, etal) The study was a prospective, randomized, double-blind, parallel-group, multicenter, 24-week study comparing placebo to memantine treatment in patients with moderate to severe AD already stabilized on donepezil. This study represents the first controlled trial to examine the safety and efficacy of treatment with an NMDA-receptor antagonist and a cholinesterase inhibitor in patients with AD. The overall objective of this study was to determine if memantine was more beneficial than donepezil in patients with moderate to severe AD. Variety of patient settings (outpatients, inpatients) MMSE scores indicative of moderate to severe AD Trial duration ranged from 12-28 weeks Double-blind portion of trials represented a total of 410 patients treated withmemantine